Service & Software

Global Oligonucleotide CDMO Market Research Report 2025

The global market for Oligonucleotide CDMO was valued at US$ 1250 million in the year 2024 and is projected to reach a revised size of US$ 2839 million by 2031, growing at a CAGR of 12.5% during the forecast period.
An Oligonucleotide CDMO (Contract Development and Manufacturing Organization) specializes in providing outsourced services related to the development and manufacturing of oligonucleotides. Oligonucleotides are short DNA or RNA molecules used for a variety of applications, including in genetic research, diagnostics, and therapeutics. These organizations are key players in the biopharmaceutical industry, helping companies bring oligonucleotide-based products from the research stage to commercialization.
North American market for Oligonucleotide CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Oligonucleotide CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Oligonucleotide CDMO in Pharmaceutical and Biotechnology Companies is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Oligonucleotide CDMO include Agilent, ST Pharm, Bachem, BioSpring, Creative Biogene, Sylentis, Ajinomoto Bio-Pharma, EUROAPI, Veliter, PolyPeptide Group, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Oligonucleotide CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide CDMO.
The Oligonucleotide CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oligonucleotide CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oligonucleotide CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Agilent
ST Pharm
Bachem
BioSpring
Creative Biogene
Sylentis
Ajinomoto Bio-Pharma
EUROAPI
Veliter
PolyPeptide Group
CordenPharma
Thermofischer
Bio Basic
Genscript
Cytiva
ScinoPharm
CBL
Piramal Pharma
CPC Scientific
Eurogentec
Cambrex
WuXi STA
Segment by Type
APIs and Intermediates
FDF
Segment by Application
Pharmaceutical and Biotechnology Companies
Research Institutes
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oligonucleotide CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oligonucleotide CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 APIs and Intermediates
1.2.3 FDF
1.3 Market by Application
1.3.1 Global Oligonucleotide CDMO Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical and Biotechnology Companies
1.3.3 Research Institutes
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oligonucleotide CDMO Market Perspective (2020-2031)
2.2 Global Oligonucleotide CDMO Growth Trends by Region
2.2.1 Global Oligonucleotide CDMO Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Oligonucleotide CDMO Historic Market Size by Region (2020-2025)
2.2.3 Oligonucleotide CDMO Forecasted Market Size by Region (2026-2031)
2.3 Oligonucleotide CDMO Market Dynamics
2.3.1 Oligonucleotide CDMO Industry Trends
2.3.2 Oligonucleotide CDMO Market Drivers
2.3.3 Oligonucleotide CDMO Market Challenges
2.3.4 Oligonucleotide CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oligonucleotide CDMO Players by Revenue
3.1.1 Global Top Oligonucleotide CDMO Players by Revenue (2020-2025)
3.1.2 Global Oligonucleotide CDMO Revenue Market Share by Players (2020-2025)
3.2 Global Top Oligonucleotide CDMO Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Oligonucleotide CDMO Revenue
3.4 Global Oligonucleotide CDMO Market Concentration Ratio
3.4.1 Global Oligonucleotide CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oligonucleotide CDMO Revenue in 2024
3.5 Global Key Players of Oligonucleotide CDMO Head office and Area Served
3.6 Global Key Players of Oligonucleotide CDMO, Product and Application
3.7 Global Key Players of Oligonucleotide CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Oligonucleotide CDMO Breakdown Data by Type
4.1 Global Oligonucleotide CDMO Historic Market Size by Type (2020-2025)
4.2 Global Oligonucleotide CDMO Forecasted Market Size by Type (2026-2031)
5 Oligonucleotide CDMO Breakdown Data by Application
5.1 Global Oligonucleotide CDMO Historic Market Size by Application (2020-2025)
5.2 Global Oligonucleotide CDMO Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Oligonucleotide CDMO Market Size (2020-2031)
6.2 North America Oligonucleotide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Oligonucleotide CDMO Market Size by Country (2020-2025)
6.4 North America Oligonucleotide CDMO Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oligonucleotide CDMO Market Size (2020-2031)
7.2 Europe Oligonucleotide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Oligonucleotide CDMO Market Size by Country (2020-2025)
7.4 Europe Oligonucleotide CDMO Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oligonucleotide CDMO Market Size (2020-2031)
8.2 Asia-Pacific Oligonucleotide CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Oligonucleotide CDMO Market Size by Region (2020-2025)
8.4 Asia-Pacific Oligonucleotide CDMO Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oligonucleotide CDMO Market Size (2020-2031)
9.2 Latin America Oligonucleotide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Oligonucleotide CDMO Market Size by Country (2020-2025)
9.4 Latin America Oligonucleotide CDMO Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oligonucleotide CDMO Market Size (2020-2031)
10.2 Middle East & Africa Oligonucleotide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Oligonucleotide CDMO Market Size by Country (2020-2025)
10.4 Middle East & Africa Oligonucleotide CDMO Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Agilent
11.1.1 Agilent Company Details
11.1.2 Agilent Business Overview
11.1.3 Agilent Oligonucleotide CDMO Introduction
11.1.4 Agilent Revenue in Oligonucleotide CDMO Business (2020-2025)
11.1.5 Agilent Recent Development
11.2 ST Pharm
11.2.1 ST Pharm Company Details
11.2.2 ST Pharm Business Overview
11.2.3 ST Pharm Oligonucleotide CDMO Introduction
11.2.4 ST Pharm Revenue in Oligonucleotide CDMO Business (2020-2025)
11.2.5 ST Pharm Recent Development
11.3 Bachem
11.3.1 Bachem Company Details
11.3.2 Bachem Business Overview
11.3.3 Bachem Oligonucleotide CDMO Introduction
11.3.4 Bachem Revenue in Oligonucleotide CDMO Business (2020-2025)
11.3.5 Bachem Recent Development
11.4 BioSpring
11.4.1 BioSpring Company Details
11.4.2 BioSpring Business Overview
11.4.3 BioSpring Oligonucleotide CDMO Introduction
11.4.4 BioSpring Revenue in Oligonucleotide CDMO Business (2020-2025)
11.4.5 BioSpring Recent Development
11.5 Creative Biogene
11.5.1 Creative Biogene Company Details
11.5.2 Creative Biogene Business Overview
11.5.3 Creative Biogene Oligonucleotide CDMO Introduction
11.5.4 Creative Biogene Revenue in Oligonucleotide CDMO Business (2020-2025)
11.5.5 Creative Biogene Recent Development
11.6 Sylentis
11.6.1 Sylentis Company Details
11.6.2 Sylentis Business Overview
11.6.3 Sylentis Oligonucleotide CDMO Introduction
11.6.4 Sylentis Revenue in Oligonucleotide CDMO Business (2020-2025)
11.6.5 Sylentis Recent Development
11.7 Ajinomoto Bio-Pharma
11.7.1 Ajinomoto Bio-Pharma Company Details
11.7.2 Ajinomoto Bio-Pharma Business Overview
11.7.3 Ajinomoto Bio-Pharma Oligonucleotide CDMO Introduction
11.7.4 Ajinomoto Bio-Pharma Revenue in Oligonucleotide CDMO Business (2020-2025)
11.7.5 Ajinomoto Bio-Pharma Recent Development
11.8 EUROAPI
11.8.1 EUROAPI Company Details
11.8.2 EUROAPI Business Overview
11.8.3 EUROAPI Oligonucleotide CDMO Introduction
11.8.4 EUROAPI Revenue in Oligonucleotide CDMO Business (2020-2025)
11.8.5 EUROAPI Recent Development
11.9 Veliter
11.9.1 Veliter Company Details
11.9.2 Veliter Business Overview
11.9.3 Veliter Oligonucleotide CDMO Introduction
11.9.4 Veliter Revenue in Oligonucleotide CDMO Business (2020-2025)
11.9.5 Veliter Recent Development
11.10 PolyPeptide Group
11.10.1 PolyPeptide Group Company Details
11.10.2 PolyPeptide Group Business Overview
11.10.3 PolyPeptide Group Oligonucleotide CDMO Introduction
11.10.4 PolyPeptide Group Revenue in Oligonucleotide CDMO Business (2020-2025)
11.10.5 PolyPeptide Group Recent Development
11.11 CordenPharma
11.11.1 CordenPharma Company Details
11.11.2 CordenPharma Business Overview
11.11.3 CordenPharma Oligonucleotide CDMO Introduction
11.11.4 CordenPharma Revenue in Oligonucleotide CDMO Business (2020-2025)
11.11.5 CordenPharma Recent Development
11.12 Thermofischer
11.12.1 Thermofischer Company Details
11.12.2 Thermofischer Business Overview
11.12.3 Thermofischer Oligonucleotide CDMO Introduction
11.12.4 Thermofischer Revenue in Oligonucleotide CDMO Business (2020-2025)
11.12.5 Thermofischer Recent Development
11.13 Bio Basic
11.13.1 Bio Basic Company Details
11.13.2 Bio Basic Business Overview
11.13.3 Bio Basic Oligonucleotide CDMO Introduction
11.13.4 Bio Basic Revenue in Oligonucleotide CDMO Business (2020-2025)
11.13.5 Bio Basic Recent Development
11.14 Genscript
11.14.1 Genscript Company Details
11.14.2 Genscript Business Overview
11.14.3 Genscript Oligonucleotide CDMO Introduction
11.14.4 Genscript Revenue in Oligonucleotide CDMO Business (2020-2025)
11.14.5 Genscript Recent Development
11.15 Cytiva
11.15.1 Cytiva Company Details
11.15.2 Cytiva Business Overview
11.15.3 Cytiva Oligonucleotide CDMO Introduction
11.15.4 Cytiva Revenue in Oligonucleotide CDMO Business (2020-2025)
11.15.5 Cytiva Recent Development
11.16 ScinoPharm
11.16.1 ScinoPharm Company Details
11.16.2 ScinoPharm Business Overview
11.16.3 ScinoPharm Oligonucleotide CDMO Introduction
11.16.4 ScinoPharm Revenue in Oligonucleotide CDMO Business (2020-2025)
11.16.5 ScinoPharm Recent Development
11.17 CBL
11.17.1 CBL Company Details
11.17.2 CBL Business Overview
11.17.3 CBL Oligonucleotide CDMO Introduction
11.17.4 CBL Revenue in Oligonucleotide CDMO Business (2020-2025)
11.17.5 CBL Recent Development
11.18 Piramal Pharma
11.18.1 Piramal Pharma Company Details
11.18.2 Piramal Pharma Business Overview
11.18.3 Piramal Pharma Oligonucleotide CDMO Introduction
11.18.4 Piramal Pharma Revenue in Oligonucleotide CDMO Business (2020-2025)
11.18.5 Piramal Pharma Recent Development
11.19 CPC Scientific
11.19.1 CPC Scientific Company Details
11.19.2 CPC Scientific Business Overview
11.19.3 CPC Scientific Oligonucleotide CDMO Introduction
11.19.4 CPC Scientific Revenue in Oligonucleotide CDMO Business (2020-2025)
11.19.5 CPC Scientific Recent Development
11.20 Eurogentec
11.20.1 Eurogentec Company Details
11.20.2 Eurogentec Business Overview
11.20.3 Eurogentec Oligonucleotide CDMO Introduction
11.20.4 Eurogentec Revenue in Oligonucleotide CDMO Business (2020-2025)
11.20.5 Eurogentec Recent Development
11.21 Cambrex
11.21.1 Cambrex Company Details
11.21.2 Cambrex Business Overview
11.21.3 Cambrex Oligonucleotide CDMO Introduction
11.21.4 Cambrex Revenue in Oligonucleotide CDMO Business (2020-2025)
11.21.5 Cambrex Recent Development
11.22 WuXi STA
11.22.1 WuXi STA Company Details
11.22.2 WuXi STA Business Overview
11.22.3 WuXi STA Oligonucleotide CDMO Introduction
11.22.4 WuXi STA Revenue in Oligonucleotide CDMO Business (2020-2025)
11.22.5 WuXi STA Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Oligonucleotide CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of APIs and Intermediates
Table 3. Key Players of FDF
Table 4. Global Oligonucleotide CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Oligonucleotide CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Oligonucleotide CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Oligonucleotide CDMO Market Share by Region (2020-2025)
Table 8. Global Oligonucleotide CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Oligonucleotide CDMO Market Share by Region (2026-2031)
Table 10. Oligonucleotide CDMO Market Trends
Table 11. Oligonucleotide CDMO Market Drivers
Table 12. Oligonucleotide CDMO Market Challenges
Table 13. Oligonucleotide CDMO Market Restraints
Table 14. Global Oligonucleotide CDMO Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Oligonucleotide CDMO Market Share by Players (2020-2025)
Table 16. Global Top Oligonucleotide CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide CDMO as of 2024)
Table 17. Ranking of Global Top Oligonucleotide CDMO Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Oligonucleotide CDMO Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Oligonucleotide CDMO, Headquarters and Area Served
Table 20. Global Key Players of Oligonucleotide CDMO, Product and Application
Table 21. Global Key Players of Oligonucleotide CDMO, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Oligonucleotide CDMO Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Oligonucleotide CDMO Revenue Market Share by Type (2020-2025)
Table 25. Global Oligonucleotide CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Oligonucleotide CDMO Revenue Market Share by Type (2026-2031)
Table 27. Global Oligonucleotide CDMO Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Oligonucleotide CDMO Revenue Market Share by Application (2020-2025)
Table 29. Global Oligonucleotide CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Oligonucleotide CDMO Revenue Market Share by Application (2026-2031)
Table 31. North America Oligonucleotide CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Oligonucleotide CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Oligonucleotide CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Oligonucleotide CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Oligonucleotide CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Oligonucleotide CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Oligonucleotide CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Oligonucleotide CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Oligonucleotide CDMO Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Oligonucleotide CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Oligonucleotide CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Oligonucleotide CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Oligonucleotide CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Oligonucleotide CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Oligonucleotide CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 46. Agilent Company Details
Table 47. Agilent Business Overview
Table 48. Agilent Oligonucleotide CDMO Product
Table 49. Agilent Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 50. Agilent Recent Development
Table 51. ST Pharm Company Details
Table 52. ST Pharm Business Overview
Table 53. ST Pharm Oligonucleotide CDMO Product
Table 54. ST Pharm Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 55. ST Pharm Recent Development
Table 56. Bachem Company Details
Table 57. Bachem Business Overview
Table 58. Bachem Oligonucleotide CDMO Product
Table 59. Bachem Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 60. Bachem Recent Development
Table 61. BioSpring Company Details
Table 62. BioSpring Business Overview
Table 63. BioSpring Oligonucleotide CDMO Product
Table 64. BioSpring Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 65. BioSpring Recent Development
Table 66. Creative Biogene Company Details
Table 67. Creative Biogene Business Overview
Table 68. Creative Biogene Oligonucleotide CDMO Product
Table 69. Creative Biogene Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 70. Creative Biogene Recent Development
Table 71. Sylentis Company Details
Table 72. Sylentis Business Overview
Table 73. Sylentis Oligonucleotide CDMO Product
Table 74. Sylentis Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 75. Sylentis Recent Development
Table 76. Ajinomoto Bio-Pharma Company Details
Table 77. Ajinomoto Bio-Pharma Business Overview
Table 78. Ajinomoto Bio-Pharma Oligonucleotide CDMO Product
Table 79. Ajinomoto Bio-Pharma Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 80. Ajinomoto Bio-Pharma Recent Development
Table 81. EUROAPI Company Details
Table 82. EUROAPI Business Overview
Table 83. EUROAPI Oligonucleotide CDMO Product
Table 84. EUROAPI Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 85. EUROAPI Recent Development
Table 86. Veliter Company Details
Table 87. Veliter Business Overview
Table 88. Veliter Oligonucleotide CDMO Product
Table 89. Veliter Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 90. Veliter Recent Development
Table 91. PolyPeptide Group Company Details
Table 92. PolyPeptide Group Business Overview
Table 93. PolyPeptide Group Oligonucleotide CDMO Product
Table 94. PolyPeptide Group Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 95. PolyPeptide Group Recent Development
Table 96. CordenPharma Company Details
Table 97. CordenPharma Business Overview
Table 98. CordenPharma Oligonucleotide CDMO Product
Table 99. CordenPharma Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 100. CordenPharma Recent Development
Table 101. Thermofischer Company Details
Table 102. Thermofischer Business Overview
Table 103. Thermofischer Oligonucleotide CDMO Product
Table 104. Thermofischer Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 105. Thermofischer Recent Development
Table 106. Bio Basic Company Details
Table 107. Bio Basic Business Overview
Table 108. Bio Basic Oligonucleotide CDMO Product
Table 109. Bio Basic Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 110. Bio Basic Recent Development
Table 111. Genscript Company Details
Table 112. Genscript Business Overview
Table 113. Genscript Oligonucleotide CDMO Product
Table 114. Genscript Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 115. Genscript Recent Development
Table 116. Cytiva Company Details
Table 117. Cytiva Business Overview
Table 118. Cytiva Oligonucleotide CDMO Product
Table 119. Cytiva Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 120. Cytiva Recent Development
Table 121. ScinoPharm Company Details
Table 122. ScinoPharm Business Overview
Table 123. ScinoPharm Oligonucleotide CDMO Product
Table 124. ScinoPharm Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 125. ScinoPharm Recent Development
Table 126. CBL Company Details
Table 127. CBL Business Overview
Table 128. CBL Oligonucleotide CDMO Product
Table 129. CBL Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 130. CBL Recent Development
Table 131. Piramal Pharma Company Details
Table 132. Piramal Pharma Business Overview
Table 133. Piramal Pharma Oligonucleotide CDMO Product
Table 134. Piramal Pharma Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 135. Piramal Pharma Recent Development
Table 136. CPC Scientific Company Details
Table 137. CPC Scientific Business Overview
Table 138. CPC Scientific Oligonucleotide CDMO Product
Table 139. CPC Scientific Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 140. CPC Scientific Recent Development
Table 141. Eurogentec Company Details
Table 142. Eurogentec Business Overview
Table 143. Eurogentec Oligonucleotide CDMO Product
Table 144. Eurogentec Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 145. Eurogentec Recent Development
Table 146. Cambrex Company Details
Table 147. Cambrex Business Overview
Table 148. Cambrex Oligonucleotide CDMO Product
Table 149. Cambrex Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 150. Cambrex Recent Development
Table 151. WuXi STA Company Details
Table 152. WuXi STA Business Overview
Table 153. WuXi STA Oligonucleotide CDMO Product
Table 154. WuXi STA Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)
Table 155. WuXi STA Recent Development
Table 156. Research Programs/Design for This Report
Table 157. Key Data Information from Secondary Sources
Table 158. Key Data Information from Primary Sources
Table 159. Authors List of This Report


List of Figures
Figure 1. Oligonucleotide CDMO Picture
Figure 2. Global Oligonucleotide CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Oligonucleotide CDMO Market Share by Type: 2024 VS 2031
Figure 4. APIs and Intermediates Features
Figure 5. FDF Features
Figure 6. Global Oligonucleotide CDMO Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Oligonucleotide CDMO Market Share by Application: 2024 VS 2031
Figure 8. Pharmaceutical and Biotechnology Companies Case Studies
Figure 9. Research Institutes Case Studies
Figure 10. Others Case Studies
Figure 11. Oligonucleotide CDMO Report Years Considered
Figure 12. Global Oligonucleotide CDMO Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Oligonucleotide CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Oligonucleotide CDMO Market Share by Region: 2024 VS 2031
Figure 15. Global Oligonucleotide CDMO Market Share by Players in 2024
Figure 16. Global Oligonucleotide CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 17. The Top 10 and 5 Players Market Share by Oligonucleotide CDMO Revenue in 2024
Figure 18. North America Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Oligonucleotide CDMO Market Share by Country (2020-2031)
Figure 20. United States Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Oligonucleotide CDMO Market Share by Country (2020-2031)
Figure 24. Germany Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Oligonucleotide CDMO Market Share by Region (2020-2031)
Figure 32. China Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Oligonucleotide CDMO Market Share by Country (2020-2031)
Figure 40. Mexico Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Oligonucleotide CDMO Market Share by Country (2020-2031)
Figure 44. Turkey Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Agilent Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)
Figure 48. ST Pharm Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)
Figure 49. Bachem Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)
Figure 50. BioSpring Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)
Figure 51. Creative Biogene Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)
Figure 52. Sylentis Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)
Figure 53. Ajinomoto Bio-Pharma Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)
Figure 54. EUROAPI Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)
Figure 55. Veliter Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)
Figure 56. PolyPeptide Group Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)
Figure 57. CordenPharma Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)
Figure 58. Thermofischer Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)
Figure 59. Bio Basic Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)
Figure 60. Genscript Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)
Figure 61. Cytiva Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)
Figure 62. ScinoPharm Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)
Figure 63. CBL Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)
Figure 64. Piramal Pharma Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)
Figure 65. CPC Scientific Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)
Figure 66. Eurogentec Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)
Figure 67. Cambrex Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)
Figure 68. WuXi STA Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies